Seeking Alpha

Endocyte falls as vintafolide monotherapy unlikely to show NSCLC PFS superiority

  • Endocyte (ECYT) plummets as the DSMB for TARGET advises investigators and patients that vintafolide monotherapy is not likely to be declared superior in PFS to docetaxel.
  • The Phase 2b trial had two arms, vintafolide monotherapy and vintafolide in combination with docetaxel, which were to be compared with standard of care (docetaxel monotherapy).
  • The DSMB did recommend the continuation of the combination therapy arm.
  • Top-line results are due early next year. (PR)
  • ECYT -27.4% premarket
Comments (3)
  • TruffelPig
    , contributor
    Comments (4108) | Send Message
     
    27% when they continue one arm? I think this is too much.
    11 Oct 2013, 08:29 AM Reply Like
  • TruffelPig
    , contributor
    Comments (4108) | Send Message
     
    Read the release - ECYT is happy with the Tax/Vintafolide arm. This is bad news and good news I say.
    Release: http://bit.ly/1bLBhbs
    11 Oct 2013, 08:34 AM Reply Like
  • TruffelPig
    , contributor
    Comments (4108) | Send Message
     
    Also to SA: the PM thus far had 2000 shares traded, lol. That is not exactly liquidity.
    11 Oct 2013, 08:40 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs